Holen Sie sich die Stockscreener-App
7.95
2.33%
-0.19
Handel nachbörslich:
8.08
0.13
+1.64%
Schlusskurs vom Vortag:
$8.14
Offen:
$8.145
24-Stunden-Volumen:
7.97M
Relative Volume:
1.79
Marktkapitalisierung:
$1.66B
Einnahmen:
$503.49M
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-30.58
EPS:
-0.26
Netto-Cashflow:
$-26.89M
1W Leistung:
-7.02%
1M Leistung:
-11.67%
6M Leistung:
+0.63%
1J Leistung:
+11.81%
1-Tages-Spanne:
$7.91
$8.16
1-Wochen-Bereich:
$7.91
$8.60
52-Wochen-Spanne:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.95 | 1.70B | 503.49M | -53.47M | -26.89M | -0.26 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire
BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Swing Trade Outlook For Every Investor - jammulinksnews.com
BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - The Globe and Mail
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketPre Market Review For Consistent Profits - jammulinksnews.com
BioCryst (BCRX) Announces Leadership Transition Plan - GuruFocus
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Ch - GuruFocus
BioCryst Pharmaceuticals announces leadership transition as CEO plans retirement - Investing.com Australia
BioCryst Pharmaceuticals announces leadership transition as CEO plans retirement By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Announces CEO Transition as Jon Stonehouse Plans Retirement and Charlie Gayer Appointed Successor - Quiver Quantitative
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - GlobeNewswire Inc.
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetPre Market Forecasts For 2025 - jammulinksnews.com
RSI Crosses Above 30 for BioCryst Pharmaceuticals Inc. — Reversal in SightGrowth Based Investment Plan Guidance Highlighted - beatles.ru
Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) To Breakeven Soon - simplywall.st
BioCryst Pharmaceuticals (BCRX) Plunges 5.38% on Upcoming Earnings, Pipeline Hurdles Weigh - AInvest
BioCryst Pharmaceuticals Inc. Sees Relief Buying After Extended DropValue Investing Picks With Stability Outlined - metal.it
Bullish Candlestick Pattern Forms in BioCryst Pharmaceuticals Inc.Trade Insight With Community Collaboration Supported - metal.it
Published on: 2025-07-29 08:08:08 - metal.it
Published on: 2025-07-29 05:16:52 - metal.it
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedBuild wealth with reliable stock picks - jammulinksnews.com
How does BioCryst Pharmaceuticals Inc. compare to its industry peersUnlock daily market insights for better decisions - jammulinksnews.com
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyDiscover stocks with explosive upside potential - jammulinksnews.com
New Product Launches: Will They Boost BioCryst Pharmaceuticals Inc. Stock in 2025AI Powered Stock Call - metal.it
How many analysts rate BioCryst Pharmaceuticals Inc. as a “Buy”Capitalize on momentum-driven investment opportunities - jammulinksnews.com
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStay ahead with daily expert stock picks - jammulinksnews.com
What are analysts’ price targets for BioCryst Pharmaceuticals Inc. in the next 12 monthsDiscover market opportunities others miss - jammulinksnews.com
Published on: 2025-07-27 20:51:34 - jammulinksnews.com
Can BioCryst Pharmaceuticals Inc. stock recover from recent declineSafe High Return Entry Points - metal.it
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsLow Risk ROI Maximization - metal.it
What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
What drives BioCryst Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - PrintWeekIndia
Why BioCryst Pharmaceuticals Inc. stock is on top investor watchlistsBreakout stock performance - jammulinksnews.com
What institutions are buying BioCryst Pharmaceuticals Inc. stock nowExceptional ROI - jammulinksnews.com
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastExceptional portfolio growth - PrintWeekIndia
BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital By Investing.com - Investing.com Canada
BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital - Investing.com
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq
Best Momentum Stock to Buy for June 4th - MSN
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):